Article Details

Lixte Biotechnology enters exclusive immuno-oncology patent license agreement with NINDS, NCI

Retrieved on: 2024-03-01 18:59:32

Tags for this article:

Click the tags to see associated articles and topics

Lixte Biotechnology enters exclusive immuno-oncology patent license agreement with NINDS, NCI. View article details on hiswai:

Excerpt

Drugs that target a receptor on immune cells called activin receptor 1C may combat tumor-induced immune suppression and help patients' immune systems ...

Article found on: cancerletter.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up